Alcobra Hopes To Continue Development In Fragile X On Quality Of Life Findings
This article was originally published in The Pink Sheet Daily
Israeli firm contends that secondary endpoints address factors that matter most to patients, clinicians and caregivers, even though its metadoxine failed on the primary efficacy measure.
You may also be interested in...
Founded in 2008, Alcobra has ridden a wave of impressive data, a friendly reception on the public markets, and growing investor interest in its bid to capture the ADHD market. Now, as it nears the start of Phase III for metadoxine, its unrelenting focus is on execution.
TTS Pharma CEO Mark Tucker discusses his ambition to bring a legal CBD oil to the UK market, following the recent submission of a European Union novel food application.
Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch
The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.